Cardiff Oncology Plans March 25 Webinar on Phase 2 Onvansertib mCRC Data
Cardiff Oncology will host a webinar on March 25, 2026 at 4:30 p.m. ET featuring two colorectal cancer experts to discuss existing clinical data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. Onvansertib, an oral PLK1 inhibitor, is in a Phase 2 trial targeting a high unmet-need patient population.
1. Webinar on mCRC Treatment Landscape
Cardiff Oncology will host a live webinar on March 25, 2026 at 4:30 p.m. ET to examine the evolving first-line RAS-mutated metastatic colorectal cancer landscape and review clinical insights for its PLK1 inhibitor, onvansertib.
2. Key Opinion Leaders
The webcast will feature Scott Kopetz, M.D., Ph.D., FACP, an MD Anderson leader in colorectal cancer research, and Heinz-Josef Lenz, M.D., a USC professor and translational oncology expert, joining interim CEO Mani Mohindru, Ph.D.
3. Onvansertib Clinical Program
Onvansertib, Cardiff’s lead oral PLK1 inhibitor, is currently enrolled in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, having shown robust single-agent activity in hard-to-treat tumors and aiming to overcome treatment resistance.
4. Access and Registration
Investors and clinicians can register for the live webcast via the Events section on the Cardiff Oncology website, with a replay available online following the session.